USP Forms Elemental Impurities Advisory Group - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

USP Forms Elemental Impurities Advisory Group


The US Pharmacopeial Convention (USP) has formed the Elemental Impurities Implementation Advisory Group and appointed members to the group from various regulatory agencies. The group will recommend implementations and general chapter adjustments to USP and will report to the Chemical Analysis Expert Committee.

According to USP, the Advisory Group was formed in accordance with the Bylaws of the USP Convention, which state, “The EVP–CEO may appoint advisory bodies to advance the work of the Council of Experts and the Convention and provide advice to staff on policy matters.” 

Dr. Roger Williams, EVP–CEO and Chair, Council of Experts, appointed the following members to the group:

  • Jon Clark, FDA
  • David Gaugh, GPhA
  • John Kauffman, FDA and ICH Q3D Rapporteur (current)
  • David Klug, IPEC–Americas
  • John Leighton, FDA
  • Robert Osterberg, USP Toxicology Expert Committee
  • John Punzi, CHPA
  • Mark Schweitzer, ICH Q3D Rapporteur (through Step 2)
  • Phyllis Walsh, NJPQCA 

USP will keep stakeholders informed through web postings on the Elemental Impurities Key Issues page, including summaries of the Advisory Group’s deliberations.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here